Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy does not work right away in the sense most people hope for. The medicine begins acting on GLP-1 receptors from the first injection, but meaningful appetite changes typically take several weeks to build, and significant weight loss is measured in months rather than days. That gap between injecting and feeling different is where a lot of confusion lives. Wegovy (semaglutide 2.4 mg) is a prescription-only medicine; a prescriber assesses whether it is clinically suitable before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is completely normal to inject your first dose and feel... nothing unusual. Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing how quickly the stomach empties and signalling the brain that you are full sooner. But that signal builds as the drug accumulates in your system. After a single 0.25 mg injection, plasma levels of semaglutide are a fraction of what they will eventually be at the 2.4 mg maintenance dose.
The titration schedule (moving from 0.25 mg up through 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, roughly every four weeks) is not arbitrary. It gives receptors time to adapt and keeps gastrointestinal discomfort manageable. The NHS semaglutide medicines page explains that it can take several weeks before the full effect on appetite is felt. Steady-state concentration (the point where the drug's level in your blood stops climbing week to week) is only reached after around four to five doses.
So if you are two weeks in and wondering whether Wegovy starts working right away or takes longer to build up, that is where almost everyone is. The pharmacology is working quietly in the background; the noticeable shift in hunger tends to arrive when the dose increases.
A shift in appetite is usually first reported around weeks four to eight, coinciding with the first or second dose increase. Some people notice a smaller appetite or an earlier feeling of fullness before that; others wait until the 1.7 mg or 2.4 mg stage. There is genuine individual variation, body weight, metabolic rate, previous dieting history and gut physiology all play a role.
Weight on the scales tends to follow appetite by a few weeks. Most of what falls away early is from eating less; the metabolic effects of sustained semaglutide exposure compound over months. The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks, that timeline exists precisely because meaningful, maintained weight loss takes sustained treatment, not a fortnight.
A practical detail worth knowing: the largest drops in appetite often happen in the 24 to 48 hours after an injection, then ease slightly before the next dose. That rhythm levels out as treatment progresses. If you are tracking your weight-loss progress, doing so weekly rather than daily gives a much more useful picture.
This is where "right away" can genuinely apply. GI side effects (nausea, loose stools, constipation, indigestion) often show up in the first few days after the initial injection or after a dose step-up. For most people they are mild to moderate and settle within one to two weeks as the body adjusts.
Fatigue and mild headache are also common in the early weeks. Injection-site reactions (redness, itching or a small lump at the site) can occur; rotating between the abdomen, thigh and upper arm helps. Rare but serious symptoms to know about include severe stomach pain that radiates to the back, which can signal pancreatitis and needs urgent medical attention. The MHRA Yellow Card scheme lets patients report any unexpected reactions directly to the regulator.
The side-effect window and the effectiveness window are not the same. Side effects front-load; effectiveness back-loads. That asymmetry catches a lot of people off guard, and if you are curious about what you can expect to feel right away when you start Wegovy, that is exactly the kind of conversation a prescriber should have with you before you start. If you have questions about whether Wegovy is right for you given your history or existing conditions, that is exactly the kind of conversation a prescriber should have with you before you start.
Yes, and this is something our prescribers are asked about regularly. Because the starter dose is a tolerability step rather than a therapeutic one, rushing the titration does not speed up results, it increases the chance of severe nausea and, in some cases, leads people to stop treatment entirely before reaching the effective maintenance dose.
The full licensed dose pathway exists in the Wegovy prescribing information; your prescriber determines when each increase is appropriate based on how you are tolerating the current level. Skipping steps or self-adjusting timing is not recommended, and anyone who buys semaglutide products online without a clinical assessment has no prescriber to make those calls. On the question of where to get Wegovy, the only legal route in the UK is a prescription from a qualified prescriber following a proper clinical assessment.
For those considering the newer single-dose 7.2 mg Wegovy pen approved by the MHRA in April 2026, the same principle applies: the titration still starts at 0.25 mg. A higher ceiling does not mean a faster start. More detail on the semaglutide treatment pathway covers what the full dose range means in practice.
If you are ready to talk through whether Wegovy is clinically appropriate for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.